4//SEC Filing
Cline Darren S 4
Accession 0000899243-21-018670
CIK 0001351288other
Filed
May 6, 8:00 PM ET
Accepted
May 7, 4:21 PM ET
Size
22.2 KB
Accession
0000899243-21-018670
Insider Transaction Report
Form 4
Cline Darren S
U.S. Chief Commercial Officer
Transactions
- Disposition to Issuer
Share Options
2021-05-05−54,192→ 0 totalExercise: $15.30Exp: 2029-05-28→ Ordinary Shares (54,192 underlying) - Disposition to Issuer
Share Options
2021-05-05−22,068→ 0 totalExercise: $0.00→ Ordinary Shares (22,068 underlying) - Disposition to Issuer
Share Options
2021-05-05−75,024→ 0 totalExercise: $0.00→ Ordinary Shares (75,024 underlying) - Disposition to Issuer
Ordinary Shares
2021-05-05−5,556→ 0 total - Disposition to Issuer
Share Options
2021-05-05−98,040→ 0 totalExercise: $0.00→ Ordinary Shares (98,040 underlying) - Disposition to Issuer
Share Options
2021-05-05−106,320→ 0 totalExercise: $0.00→ Ordinary Shares (106,320 underlying) - Disposition to Issuer
Share Options
2021-05-05−177,180→ 0 totalExercise: $0.00→ Ordinary Shares (177,180 underlying) - Disposition to Issuer
Share Options
2021-05-05−46,896→ 0 totalExercise: $0.00→ Ordinary Shares (46,896 underlying)
Footnotes (5)
- [F1]On May 5, 2021, Jazz Pharmaceuticals Public Limited Company, a public limited company incorporated in the Republic of Ireland ("Jazz"), Jazz Pharmaceuticals UK Holdings Limited, a private limited company incorporated in England and Wales and an indirect wholly owned subsidiary of Jazz ("Bidco") and the DR Nominee (as defined in the Transaction Agreement) acquired all outstanding ordinary shares, par value British Pound Sterling 0.001 per share, of GW Pharmaceuticals plc, a public limited company incorporated in England and Wales (the "Company"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement") (continued in footnote 2).
- [F2]At the effective time of the Scheme of Arrangement, Scheme Shareholders (as defined in the Scheme of Arrangement) became entitled to receive for each Scheme Share (as defined in the Scheme of Arrangement) held by them an amount equal to $16.66 2/3 in cash plus 0.010030 ordinary shares, nominal value $0.0001 per share, of Jazz ("Jazz ordinary shares"). The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on March 15, 2021.
- [F3]Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration.
- [F4]Pursuant to the Transaction Agreement, one-third of these share options vested and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration, and the remaining two-thirds were converted into an option to acquire Jazz ordinary shares (with any performance goals deemed fully satisfied), half of which will vest on March 2, 2022 and half of which will vest on March 2, 2023.
- [F5]These stock options were granted with automatic vesting on exercisable date.
Documents
Issuer
GW PHARMACEUTICALS PLC
CIK 0001351288
Entity typeother
Related Parties
1- filerCIK 0001633639
Filing Metadata
- Form type
- 4
- Filed
- May 6, 8:00 PM ET
- Accepted
- May 7, 4:21 PM ET
- Size
- 22.2 KB